

Overview of Breast Cancer

Gary W. Unzeitig, M.D., F.A.C.S Laredo, Texas


No Disclosures



OBJECTIVES

- Brief overview of breast cancer
- Discuss the diagnosis and treatment phases of breast cancer and decision making
- Discuss the rationale for neoadjuvant treatment and tumor biology
- Overview of some open trials





TNM System

TisCarcinoma in situT12 cm or lessT2> 2 but \leq 5 cmT3Greater then 5 cmT4Skin, chest wall
involvement, or
inflammatory



Remember, though, that a cell that appears poorly differentiated does not necessarily function poorly.

STAGING OF CANCER







Bones STAGE IV

Lungs

Liver

STAGE I

Disease is confined to the breast, with or without dimpling of the skin.

STAGE II

The tumor is larger and the axillary nodes may be affected. Surgery may cure, but some systemic treatment is usually advised.

STAGE III

Cancer has invaded the muscles of the chest wall, the overlying skin, or possibly the lymph nodes above the collarbone. STAGE IV The cancer has spread to elsewhere in the body, typically the bones, liver, or lungs.

biopsy

surgery radiation systemic therapy

what order??



Neoadjuvant treatment



http://www3.mdanderson.org/app/medca lc/index.cfm?pagename=jsconvert3

invert3 P • C C Residual Cancer Burden Cal ×	
THE GNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History	Request an appointment You can help: Give now International Center S English • myMDAnderson Newsroom •
Patient and Cancer Information	Education and Research Q Keyword Search
Home	E-mail 🖾 Print 👼 Text Size 💩 🔿
Residual Cancer Burden Calculator	
	"Values must be entered into all fields for the calculation results to be accurate. (1) Primary Tumor Bed Primary Tumor Bed Area: (mm) X (mm) Overall Cancer Cellularity (as percentage of area): (%) Percentage of Cancer That is <i>in altu</i> Disease: (%) (2) Lymph Nodes Number of Positive Lymph Nodes: Diameter of Largest Metastasis: (mm) Reset Calculate



A011106

ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study (A011106)



Inclusion Criteria


- ECOG performance status 0-2
- Postmenopausal women
- Clinical T2-T4c, any N, M0 invasive breast cancer
- ER+ with an Allred score of 6, 7 or 8 (ER% > 67%)
- HER2-
- Agree to required research biopsies at baseline, week 4 and at surgery

Exclusion Criteria

- Surgical axillary staging procedure prior to study entry.
 Note: FNA or core needle biopsy of axillary node is permitted.
- History of invasive breast cancer or contralateral DCIS.



ALTERNATE Schema N= 1,740 - 2,820






A011202

A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after receiving neoadjuvant chemotherapy

Judy C. Boughey MD, Bruce G. Haffty MD, Thomas Buchholz MD, W. Fraser Symmans MD, Kelly K. Hunt MD, Jane Armer, PhD, RN, Janice Cormier, MD, Vera Suman PhD

Node Positive Neoadjuvant Patients




Alliance A11104/ACRIN 6694

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Eligibility criteria

- Women with
 - her-2 positive breast cancer (ER/PR negative) OR
 - Triple negative breast cancer
- Stage I-II, unilateral cancer
- No previous breast cancer history
- No preoperative chemotherapy
- No plans for partial breast irradiation following lumpectomy
- No BRCA carriers

Alliance A11104 Phase III trial



Sample size: 244 patients/arm

Eligibility criteria


- Women with
 - her-2 positive breast cancer (ER/PR negative) OR
 - Triple negative breast cancer
- Stage I-II, unilateral cancer
- No previous breast cancer history
- No preoperative chemotherapy
- No plans for partial breast irradiation following lumpectomy
- No BRCA carriers

Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (Alliance 011401)

The <u>Breast cancer WEight Loss</u> (BWEL) Study

PI Jennifer Ligibel Co-PI Pamela Goodwin

BWEL Study Schema



Conducted through NCTN/NCORP

Activation date: August 29, 2016

Select Eligibility Criteria

- Breast cancer diagnosed within past 12 months
- Her-2 negative
- Stage II-III
 - Triple negative tumors: T2-T3, N0-3; any T, N1-3
 - ER+: any T, N1-3
- Completed with all chemotherapy and surgery (current radiation and hormonal, bisphosphonate, and biologic therapies okay)
- Life expectancy from other causes at least 5 years
- BMI ≥ 27 kg/m2
- Pre- or postmenopausal

drgwu@laredobreastcare.com